Weight loss drug and IUD for early uterine cancer
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests a weight-loss drug called tirzepatide (given as a shot) along with a progesterone-releasing intrauterine device (IUD) to treat early-stage endometrial cancer or a precancerous condition of the uterine lining. The goal is to see if this combination can reverse the abnormal cells without surgery, which may help women who are overweight or obese by addressing weight as a risk factor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atypical hyperplasia (a precancerous change in the uterine lining) or grade 1 endometrial cancer (the earliest stage of uterine cancer), and you choose not to have surgery.
- You are overweight (BMI of 27 or higher with a weight-related condition like high blood pressure, diabetes, or high cholesterol) or obese (BMI of 30 or higher).
- You are 18 years or older.
- You have not taken certain diabetes or weight-loss medications in the past, like Ozempic or Victoza, and you are not currently using insulin.
- You are not pregnant and are willing to use contraception if you could become pregnant.
- You have no significant heart, liver, or lung disease, and no other active cancer (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a weight-loss medication called semaglutide combined with a hormonal intrauterine device (IUD) can help treat early-stage endometrial cancer or precancerous changes, allowing patients who want to preserve fertility or avoid surgery to do so. The study also includes a structured weight loss program.
This study tests a weight-loss medication (tirzepatide) combined with a hormonal intrauterine device (IUD) to treat early-stage endometrial cancer or precancerous changes. The goal is to see if this approach can make the condition go away and possibly avoid more invasive surgery.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests if adding a GLP-1 weight-loss drug to a hormone-releasing IUD can help treat very early endometrial cancer or a precancerous condition in women with obesity. The goal is to see if this combination is effective without surgery.
Hear when a new Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.